{"product_id":"sunpharma-marketing-mix","title":"Sun Pharma Industries Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReady-Made Marketing Analysis, Ready to Use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSun Pharma leverages a diversified product portfolio—from generics to specialty therapies—paired with competitive pricing and expansive global distribution to maintain market leadership in pharmaceuticals.\u003c\/p\u003e\n\u003cp\u003eIts promotion mixes regulatory-compliant medical communications, targeted physician outreach, and digital education campaigns to build trust and drive prescriptions.\u003c\/p\u003e\n\u003cp\u003eGo beyond this snapshot—purchase the full 4P's Marketing Mix Analysis for Sun Pharma Industries to get an editable, presentation-ready report with detailed strategy, data, and actionable recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Specialty Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy end-2025 Sun Pharma Industries strengthened its Global Specialty Portfolio, with specialty segments (dermatology, ophthalmology, oncology) contributing an estimated 28% of consolidated revenues—up from ~20% in 2022—driven by brands Ilumya, Cequa, and Winlevi which together account for roughly $850m in annual sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Generic Formulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSun Pharma Industries maintains a vast catalog of generic medicines across cardiology, psychiatry, and gastroenterology, driving global reach with generics contributing about 70% of revenue (FY2024 revenue ₹38,000 crore; generics ≈ ₹26,600 crore).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActive Pharmaceutical Ingredients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs a vertically integrated player, Sun Pharma Industries produces a broad mix of Active Pharmaceutical Ingredients (APIs) that meet internal demand and supply external clients, supporting ~20% of group sales from specialty and complex molecules in FY2024–25; this reduces reliance on third-party suppliers and limits disruption risk. By controlling raw-material stages, Sun Pharma enforces strict quality controls and cut manufacturing costs—management cites API-driven gross-margin uplift of ~150–250 bps versus peers. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Healthcare and OTC Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSun Pharma’s Consumer Healthcare arm sells OTC brands like Revital and Volini across India and 60+ export markets, driving roughly INR 2,300 crore in FY2024 revenue for the consumer segment and contributing a stable, higher-margin cash flow versus Rx products.\u003c\/p\u003e\n\u003cp\u003eThese SKUs target wellness, pain relief, and nutrition, use TV\/retail\/digital marketing to leverage strong brand recall, and lower regulatory risk from prescription-only rules—helping diversify Sun Pharma’s revenue mix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRevital, Volini: flagship OTC brands\u003c\/li\u003e\n\u003cli\u003ePresence: India + 60+ countries\u003c\/li\u003e\n\u003cli\u003eConsumer segment revenue: ~INR 2,300 crore (FY2024)\u003c\/li\u003e\n\u003cli\u003eBenefits: higher margins, steady cash flow, lower Rx regulation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Research and Development Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSun Pharma invests roughly INR 6.5 billion (2024 R\u0026amp;D spend) annually to sustain First-to-File and complex generic pipelines, targeting specialty delivery systems and biosimilars to drive late-2020s growth.\u003c\/p\u003e\n\u003cp\u003eThe pipeline emphasizes high-value clinical candidates addressing oncology and immunology unmet needs and positions the company for patent cliffs of major biologics expected 2026–2030.\u003c\/p\u003e\n\u003cp\u003ePrioritizing complex generics and biosimilars aims to boost margins and reduce launch risk versus standard generics.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eINR 6.5B R\u0026amp;D (2024)\u003c\/li\u003e\n\u003cli\u003eFocus: specialty delivery, biosimilars\u003c\/li\u003e\n\u003cli\u003eTarget window: 2026–2030 patent cliffs\u003c\/li\u003e\n\u003cli\u003eStrategy: First-to-File, high-value clinical candidates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSun Pharma 2025: 28% Specialty, 70% Generics — ₹38,000cr FY24 with ₹650cr R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBy end-2025 Sun Pharma’s product mix: specialty portfolio ~28% revenue (~$850m brands Ilumya\/Cequa\/Winlevi), generics ~70% (FY2024 revenue ₹38,000 crore; generics ≈ ₹26,600 crore), consumer OTC ~INR 2,300 crore; R\u0026amp;D INR 650 crore (2024) targeting complex generics\/biosimilars for 2026–2030 cliffs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty %\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics %\u003c\/td\u003e\n\u003ctd\u003e70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 Rev\u003c\/td\u003e\n\u003ctd\u003e₹38,000 cr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTC Rev\u003c\/td\u003e\n\u003ctd\u003e₹2,300 cr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D 2024\u003c\/td\u003e\n\u003ctd\u003e₹650 cr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Sun Pharma Industries’ Product, Price, Place, and Promotion strategies, ideal for managers, consultants, and marketers needing a complete breakdown of the company’s marketing positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Sun Pharma’s 4P marketing strategy into a concise, leadership-friendly snapshot highlighting product portfolio strengths, pricing strategy, distribution reach and promotional levers to quickly align teams and inform strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Global Manufacturing Footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSun Pharma operates over 40 manufacturing facilities across India, the US, Hungary and other markets, producing injectables, topicals and oral solids; in FY2024 the company reported capital expenditure of ~INR 2,200 crore to expand capacity. Localized sites cut lead times and helped sustain 98% on-time supply during 2023–24, while diversifying geography reduced single-country supply risk after 2020 disruptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Indian Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSun Pharma uses over 200 carrying and forwarding agents to supply more than 500,000 retail pharmacies across India, ensuring chronic and acute drugs reach remote districts; this network supported domestic revenue of INR 80,000 crore in FY2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Presence in the United States\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe United States is Sun Pharma Industries’ largest market, accounting for about 38% of consolidated revenues in FY2024 (roughly $2.8bn of $7.4bn total), supported by a distribution network linked to major wholesalers and pharmacy benefit managers. The company operates local warehouses and a dedicated specialty sales force to ensure access for hospitals, clinics, and retail pharmacies. This regional focus drives commercial success for high‑value specialty dermatology and ophthalmology portfolios, which contributed an estimated 22% of US revenues in 2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion into Emerging Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSun Pharma serves over 80 emerging markets across Southeast Asia, Africa, and Latin America, contributing roughly 18% of consolidated revenue in FY2024 (about USD 1.6bn of USD 8.9bn total).\u003c\/p\u003e\n\u003cp\u003eIt tailors distribution to local infrastructure—mixing cold-chain, last-mile distributors, and digital channels—to capture rising healthcare access where pharma spending grew ~6% CAGR 2019–2024.\u003c\/p\u003e\n\u003cp\u003eMarkets use direct subsidiaries plus local partners to manage regulation; partnerships account for ~40% of emerging-market sales to 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e80+ markets served\u003c\/li\u003e\n\u003cli\u003e~18% of FY2024 revenue (~USD 1.6bn)\u003c\/li\u003e\n\u003cli\u003e~6% pharm spending CAGR (2019–2024)\u003c\/li\u003e\n\u003cli\u003e~40% sales via local partners\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Supply Chain and E-Pharmacy Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSun Pharma has deployed AI-driven inventory systems across 60+ manufacturing and distribution sites by 2025, cutting stock-outs 28% and lowering carry costs ~12% year-over-year.\u003c\/p\u003e\n\u003cp\u003eThe company partners with leading Indian e-pharmacies and 45 regional platforms, driving a 22% rise in online channel sales in 2024 and widening urban reach.\u003c\/p\u003e\n\u003cp\u003eThis omnichannel setup keeps medicines stocked in 150,000 retail outlets while scaling digital storefronts, supporting a blended revenue mix that improved gross margin 0.8 ppt in FY2024–25.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAI inventory: 60+ sites, −28% stock-outs\u003c\/li\u003e\n\u003cli\u003eE-pharmacy tie-ups: 45 platforms, +22% online sales\u003c\/li\u003e\n\u003cli\u003eRetail reach: 150,000 outlets\u003c\/li\u003e\n\u003cli\u003eMargin impact: +0.8 ppt FY2024–25\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSun Pharma: 40+ plants, AI cut stock-outs 28%, US ~38% revenue, 150k retail reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSun Pharma’s place mix: 40+ plants (INR 2,200cr capex FY2024), 200+ C\u0026amp;F agents, 150,000 retail outlets, 80+ emerging markets (~18% revenue, ~USD1.6bn FY2024), US ~38% revenue (~USD2.8bn FY2024); AI inventory at 60+ sites (−28% stock-outs), 45 e‑pharmacy partners (+22% online sales 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlants\u003c\/td\u003e\n\u003ctd\u003e40+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex FY2024\u003c\/td\u003e\n\u003ctd\u003eINR 2,200cr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS revenue\u003c\/td\u003e\n\u003ctd\u003e~38% (~USD2.8bn)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmerging markets\u003c\/td\u003e\n\u003ctd\u003e80+, ~18% (~USD1.6bn)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail reach\u003c\/td\u003e\n\u003ctd\u003e150,000 outlets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI sites\u003c\/td\u003e\n\u003ctd\u003e60+, −28% stock-outs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eSun Pharma Industries 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual document you’ll receive instantly after purchase—no surprises. This Sun Pharma Industries 4P's Marketing Mix Analysis covers Product, Price, Place and Promotion with clear insights, strategic recommendations and ready-to-use visuals. It's the same comprehensive, editable file you'll download immediately after checkout. Buy with confidence—what you see is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750020362617,"sku":"sunpharma-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/sunpharma-marketing-mix.png?v=1772221436","url":"https:\/\/matrixbcg.com\/products\/sunpharma-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}